Phase II results reported for AXL inhibitor bemcentinib in patients failing hypomethylating agents Dec. 31, 2020
Primary endpoint not met in phase III trial of eprenetapopt in TP53-mutant myelodysplastic syndromes Dec. 28, 2020
RSS